Cystic Fibrosis Clinical Trial
Official title:
The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients
Accurate identification of lower respiratory tract pathogens is standard of care in the management of CF patients and it is therefore recommended to perform regular bacterial cultures, at least once a year, but some even recommend monthly cultures. This can be done through different methods, of which sputum and bronchoalveolar lavage (BAL) are the gold standard. However, BAL is an invasive method, not designated to repeat monthly. Therefore, the diagnosis of lower respiratory tract infections can be challenging in the non-expectorating CF patient. Other methods, such as induced sputum (IS), cough swabs and nasal swabs, have been developed to obtain bacterial cultures in these patients. Studies have investigated the reliability of these different sampling methods, however, with controversial conclusions.
I. Protocol design:
The current protocol is designed to compare:
- Group 1: nasal swab, cough swab and spontaneous expectorated sputum in expectorating CF
patients
- Group 2: nasal swab, cough swab and induced sputum in non-expectorating CF patients
- Group 3: nasal swab, cough swab, induced sputum and BAL in both expectorating and
non-expectorating CF patients requiring clinically indicated bronchoscopy
II. Flow chart:
1. Nasal swab obtained by the physiotherapyst (PT)
2. Patient rinses his mouth with water, followed by autogenic drainage
3. Cough swab obtained by the PT
4. Obtainment of 3rd (4th) sample:
- Group 1: Sputum sample voluntary expectorated by the patient
- Group 2 and 3: Induced sputum sample --> voluntary coughed up and expectorated by
the patient after inhalation of 4ml of HS OR
- Group 3: BAL -->obtained by the pulmonologist during bronchoscopy
5. Filling out questionnaire on acceptability of the different sampling methods by
patients >6 years of age (not in Group 3)
III. Analysis of the samples:
(Induced) Sputum samples, cough and nasal swabs are aseptically collected in the appropriate
disposable and are immediately sent to the Laboratory for Microbiology and Infection Control
of the Universitair Ziekenhuis Brussel, where analyses are carried out within 24h
post-sampling.
These analyses include:
- Culture and identification of respiratory pathogens on selective and non-selective
media
- Each type of colony will be identified by MALDI-TOF mass spectrometry, completed by
other identification tests if needed
- When appropriate, susceptibility tests will be performed on the isolated bacteria
IV. Statistical analysis:
- Determination of sensitivity, specificity, positive predicted value, negative predicted
value of the different sampling methods
- Preference for one method over another: crosstabs, Chi-square test
- Pain experienced with any method (Yes/No): Student's t-test
- VAS-scale pain per method: ANOVA
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |